David P Carbone, MD, PHD
Leadership Title: Barbara J. Bonner Chair in Lung Cancer Research Director, James Thoracic Center Co-Leader, Translational Therapeutics Program
Academic Title: Professor in the College of Medicine
Research Program: Translational Therapeutics
I am a medical oncologist who specializes in creating cutting-edge treatments for patients with lung cancer. This is a disease with unacceptable outcomes, but there are many promising therapies today and on the horizon. I was named to the Castle Connolly list of “America's Top Doctors” from 2004 to 2019 and rated in the top 10 percent of physicians in the nation for patient satisfaction in 2016. I serve as a professor of internal medicine at The Ohio State University and co-leader of the Translational Therapeutics Program at the OSUCCC – James, where I also direct the Thoracic Oncology Center. In addition, I am the president of the International Association for the Study of Lung Cancer (IASLC) and hold the Barbara J. Bonner Chair in Lung Cancer Research. My research is focused specifically on proteomic and expression array signature development, genetics, immunotherapy and tumor-associated immunosuppression mechanisms in lung cancer. Some of my recent research directions include the development of molecular biomarkers to guide patient management and therapy, and molecular profiling of lung cancers and pre-neoplasias to guide the development of therapeutics, especially using mass spectrometry-based proteomics. I’ve served as an investigator on multiple clinical trials, including the large phase III lung cancer trials, for the Eastern Cooperative Oncology Group (ECOG), one of the largest clinical cancer research organizations in the U.S. Additionally, I’ve authored more than 250 peer-reviewed publications, book chapters and articles. I have served on several National Cancer Institute (NCI) grant review panels and the NCI Board of Scientific Counselors. I am also a past president of the International Association for the Study of Lung Cancer and current co-chair of the NCI CTEP Thoracic Malignancies Steering Committee. In 2012, I came to Ohio State from Vanderbilt University to establish and direct the OSUCCC – James thoracic center. With our multidisciplinary team approach, we apply advanced molecular diagnostics and state-of-the-art therapeutics to provide personalized care every lung cancer patient. The collaborative spirit, team approach, dedicated patient care and enlightened leadership we enjoy at the OSUCCC – James all come together together to make this a great place to work and a great place to receive treatment for cancer.
- Lung Cancers
- Carcinoma, Non-Small-Cell Lung
- Mesothelioma
- Carcinoma, Squamous Cell
- Small Cell Lung Carcinoma
- Carcinoma
- Neoplasms
- Carcinoma, Non-Small Cell Lung
- Lung Neoplasms
- Adenocarcinoma
- Neoplasm Metastasis
Internship - Internal Medicine
- Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD
Residency - Internal Medicine
- Johns Hopkins Bayview Medical Center
4940 Eastern Ave, Baltimore, MD
Graduate
- Johns Hopkins University School of Medicine
733 N Broadway, Baltimore, MD
Medical School - Internal Medicine
- Johns Hopkins University School of Medicine
733 N Broadway, Baltimore, MD
Fellowship - Medical Oncology
- National Cancer Institute, NIH
9000 Rockville Pike, Bethesda, MD
- Johns Hopkins Bayview Medical Center
Academic Office:
Biomedical Research Tower 0488
460 W 12th Ave
Columbus, Ohio 43210-2210Phone:
614-685-4479Email:
carbone.41@osu.eduPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
- October 28, 2024
Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma.
Exp Hematol Oncol
October 9, 2024CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.
Skoulidis F, Araujo HA, Do MT, Qian Y, Sun X, Cobo AG, Le JT, Montesion M, Palmer R, Jahchan N, Juan JM, Min C, Yu Y, Pan X, Arbour KC, Vokes N, Schmidt ST, Molkentine D, Owen DH, Memmott R, Patil PD, Marmarelis ME, Awad MM, Murray JC, Hellyer JA, Gainor JF, Dimou A, Bestvina CM, Shu CA, Riess JW, Blakely CM, Pecot CV, Mezquita L, Tabbó F, Scheffler M, Digumarthy S, Mooradian MJ, Sacher AG, Lau SCM, Saltos AN, Rotow J, Johnson RP, Liu C, Stewart T, Goldberg SB, Killam J, Walther Z, Schalper K, Davies KD, Woodcock MG, Anagnostou V, Marrone KA, Forde PM, Ricciuti B, Venkatraman D, Van Allen EM, Cummings AL, Goldman JW, Shaish H, Kier M, Katz S, Aggarwal C, Ni Y, Azok JT, Segal J, Ritterhouse L, Neal JW, Lacroix L, Elamin YY, Negrao MV, Le X, Lam VK, Lewis WE, Kemp HN, Carter B, Roth JA, Swisher S, Lee R, Zhou T, Poteete A, Kong Y, Takehara T, Paula AG, Parra Cuentas ER, Behrens C, Wistuba II, Zhang J, Blumenschein GR, Gay C, Byers LA, Gibbons DL, Tsao A, Lee JJ, Bivona TG, Camidge DR, Gray JE, Lieghl N, Levy B, Brahmer JR, Garassino MC, Gandara DR, Garon EB, Rizvi NA, Scagliotti GV, Wolf J, Planchard D, Besse B, Herbst RS, Wakelee HA, Pennell NA, Shaw AT, Jänne PA, Carbone DP, Hellmann MD, Rudin CM, Albacker L, Mann H, Zhu Z, Lai Z, Stewart R, Peters S, Johnson ML, Wong KK, Huang A, Winslow MM, Rosen MJ, Winters IP, Papadimitrakopoulou VA, Cascone T, Jewsbury P, Heymach JV
Nature
October 4, 2024Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab-Based Treatment in Patients With Metastatic Non-Small Cell Lung Cancer and Tumor PD-L1 <1%: a Pooled Analysis.
Peters S, Paz-Ares LG, Reck M, Carbone DP, Brahmer JR, Borghaei H, Lu S, O'Byrne KJ, John T, Ciuleanu TE, Schenker M, Caro RB, Nishio M, Cobo M, Lee JS, Zurawski B, Pluzanski A, Aoyama T, Tschaika M, Devas V, Grootendorst DJ, Ramalingam SS
J Thorac Oncol
September 17, 2024A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6-Targeting Antibody-Drug Conjugate, in Patients With Small Cell Lung Cancer.
Morgensztern D, Ready N, Johnson ML, Dowlati A, Choudhury N, Carbone DP, Schaefer E, Arnold SM, Puri S, Piotrowska Z, Hegde A, Chiang AC, Iams W, Tolcher A, Nosaki K, Kozuki T, Li T, Santana-Davila R, Akamatsu H, Murakami H, Yokouchi H, Wang S, Zha J, Li R, Robinson RR, Hingorani P, Jeng EE, Furqan M
Clin Cancer Res
August 25, 2024Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial.
Reck M, Ciuleanu TE, Schenker M, Bordenave S, Cobo M, Juan-Vidal O, Reinmuth N, Richardet E, Felip E, Menezes J, Cheng Y, Mizutani H, Zurawski B, Alexandru A, Carbone DP, Lu S, John T, Aoyama T, Grootendorst DJ, Hu N, Eccles LJ, Paz-Ares LG
Eur J Cancer
August 21, 2024Resiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer.
Presley CJ, Grogan M, Compston A, Hock K, Knauss B, Redder E, Arrato NA, Lo SB, Janse S, Benedict J, Hoyd R, Williams N, Hayes S, Wells-Di Gregorio S, Gill TM, Allore H, Focht B, Quist M, Carbone DP, Spakowicz D, Paskett ED, Andersen BL
J Geriatr Oncol
August 8, 2024Ancestry-, Sex-, and Age-Based Differences of Gene Alterations in NSCLC: From the Real-World Data of Cancer Genomic Profiling Tests.
Miura K, Shukuya T, Greenstein R, Kaplan B, Wakelee H, Kurokawa K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K
J Natl Compr Canc Netw
July 25, 2024Atezolizumab Before and After Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II Nonrandomized Controlled Trial.
Ross HJ, Kozono D, Wang XF, Urbanic JJ, Williams TM, Nelson GD, Carbone DP, Chung D, Robb R, Byun WY, Talabere T, DuFrane C, Bara I, Schulze K, Brockman M, Gao J, Vokes EE, Stinchcombe TE
JAMA Oncol
July 13, 2024Calls to action on lung cancer management and research.
Meyer ML, Hirsch FR, Bunn PA, Ujhazy P, Fredrickson D, Berg CD, Carbone DP, Halmos B, Singh H, Borghaei H, Ferris A, Langer C, Dacic S, Mok TS, Peters S, Johnson BE
Oncologist
May 10, 2024DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M, Carbone D, Li Z, He K
Mol Cancer
April 6, 2024Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.
Divan HA, Bittoni MA, Krishna A, Carbone DP
BMC Cancer
April 5, 2024CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.
Khorasanchi A, Zhao S, Wei L, Li M, Ho K, Abu-Sbeih H, Goodyear E, Secor A, Shields P, He K, Kaufman J, Memmott R, Alahmadi A, Carbone D, Otterson G, Meara A, Presley C, Owen D
J Natl Compr Canc Netw
April 1, 2024Development of new techniques and clinical applications of liquid biopsy in lung cancer management.
Chen K, He Y, Wang W, Yuan X, Carbone DP, Yang F
Sci Bull (Beijing)
March 27, 2024A shared neoantigen vaccine combined with immune checkpoint blockade for advanced metastatic solid tumors: phase 1 trial interim results.
Rappaport AR, Kyi C, Lane M, Hart MG, Johnson ML, Henick BS, Liao CY, Mahipal A, Shergill A, Spira AI, Goldman JW, Scallan CD, Schenk D, Palmer CD, Davis MJ, Kounlavouth S, Kemp L, Yang A, Li YJ, Likes M, Shen A, Boucher GR, Egorova M, Veres RL, Espinosa JA, Jaroslavsky JR, Kraemer Tardif LD, Acrebuche L, Puccia C, Sousa L, Zhou R, Bae K, Hecht JR, Carbone DP, Johnson B, Allen A, Ferguson AR, Jooss K
Nat Med
March 1, 2024Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung Cancer.
Christopoulos P, Harel M, McGregor K, Brody Y, Puzanov I, Bar J, Elon Y, Sela I, Yellin B, Lahav C, Raveh S, Reiner-Benaim A, Reinmuth N, Nechushtan H, Farrugia D, Bustinza-Linares E, Lou Y, Leibowitz R, Kamer I, Zer Kuch A, Moskovitz M, Levy-Barda A, Koch I, Lotem M, Katzenelson R, Agbarya A, Price G, Cheley H, Abu-Amna M, Geldart T, Gottfried M, Tepper E, Polychronis A, Wolf I, Dicker AP, Carbone DP, Gandara DR
JCO Precis Oncol
February 21, 2024A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
Mason M, Lapuente-Santana Ó, Halkola AS, Wang W, Mall R, Xiao X, Kaufman J, Fu J, Pfeil J, Banerjee J, Chung V, Chang H, Chasalow SD, Lin HY, Chai R, Yu T, Finotello F, Mirtti T, Mäyränpää MI, Bao J, Verschuren EW, Ahmed EI, Ceccarelli M, Miller LD, Monaco G, Hendrickx WRL, Sherif S, Yang L, Tang M, Gu SS, Zhang W, Zhang Y, Zeng Z, Das Sahu A, Liu Y, Yang W, Bedognetti D, Tang J, Eduati F, Laajala TD, Geese WJ, Guinney J, Szustakowski JD, Vincent BG, Carbone DP
J Transl Med
February 20, 2024A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Williams TM, Miller E, Welliver M, Brownstein J, Otterson G, Owen D, Haglund K, Shields P, Bertino E, Presley C, He K, Naduparambil J, Walston S, Pan J, Yang X, Knopp M, Essan JK, McElroy J, Mo X, McElroy S, Carbone D, Bazan J
Int J Radiat Oncol Biol Phys
February 12, 2024Four-year clinical update and treatment switching-adjusted outcomes with first-line nivolumab plus ipilimumab with chemotherapy for metastatic non-small cell lung cancer in the CheckMate 9LA randomized trial.
Carbone DP, Ciuleanu TE, Schenker M, Cobo M, Bordenave S, Juan-Vidal O, Menezes J, Reinmuth N, Richardet E, Cheng Y, Mizutani H, Felip E, Zurawski B, Alexandru A, Paz-Ares L, Lu S, John T, Zhang X, Mahmood J, Hu N, De T, Santi I, Penrod JR, Yuan Y, Lee A, Reck M
J Immunother Cancer
January 1, 2024Vaping, Smoking and Lung Cancer Risk.
Bittoni MA, Carbone DP, Harris RE
J Oncol Res Ther
December 7, 2023Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with non-small cell lung cancer: results from the LCMC3 study.
Dacic S, Travis WD, Giltnane JM, Kos F, Abel J, Hilz S, Fujimoto J, Sholl L, Ritter J, Khalil F, Liu Y, Taylor-Weiner A, Resnick M, Yu H, Hirsch FR, Bunn PA, Carbone DP, Rusch V, Kwiatkowski DJ, Johnson BE, Lee JM, Hennek SR, Wapinski I, Nicholas A, Johnson A, Schulze K, Kris MG, Wistuba II
J Thorac Oncol
November 1, 2023Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K
J Natl Compr Canc Netw
October 18, 2023Exogenous sequences in tumors and immune cells (exotic): a tool for estimating the microbe abundances in tumor RNAseq data.
Hoyd R, Wheeler CE, Liu Y, Jagjit Singh MS, Muniak M, Jin N, Denko NC, Carbone DP, Mo X, Spakowicz DJ
Cancer Res Commun
October 10, 2023Author Correction: Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP, LCMC study investigators
Nat Med
September 11, 2023Genomic characterization of thymic epithelial tumors in a real-world dataset.
Kurokawa K, Shukuya T, Greenstein RA, Kaplan BG, Wakelee H, Ross JS, Miura K, Furuta K, Kato S, Suh J, Sivakumar S, Sokol ES, Carbone DP, Takahashi K
ESMO Open
September 1, 2023Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer.
Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, Wu S, Qiu F, Peng D, Zhu X, Chuai S, Beck S, Kanu N, Carbone D, Zhang Z, Wang J
Cancer Cell
August 14, 2023Germline EGFR mutations and familial lung cancer.
Oxnard GR, Chen R, Pharr JC, Koeller DR, Bertram AA, Dahlberg SE, Rainville I, Shane-Carson K, Taylor KA, Sable-Hunt A, Sholl LM, Teerlink CC, Thomas A, Cannon-Albright LA, Fay AP, Ashton-Prolla P, Yang H, Salvatore MM, Addario BJ, Jänne PA, Carbone DP, Wiesner GL, Garber JE
J Clin Oncol
May 17, 2023Improving combination therapies: Targeting A2B adenosine receptor to modulate metabolic tumor microenvironment and immunosuppression.
Evans JV, Suman S, Goruganthu MUL, Tchekneva EE, Guan S, Arasada RR, Antonucci A, Piao L, Ilgisonis I, Bobko AA, Driesschaert B, Uzhachenko RV, Hoyd R, Samouilov A, Amann J, Wu R, Wei L, Pallerla A, Ryzhov SV, Feoktistov I, Park KP, Kikuchi T, Castro J, Ivanova AV, Kanagasabai T, Owen DH, Spakowicz DJ, Zweier JL, Carbone DP, Novitskiy SV, Khramtsov VV, Shanker A, Dikov MM
J Natl Cancer Inst
April 21, 2023Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer.
Johns AC, Yang M, Wei L, Grogan M, Spakowicz D, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Rosko AE, Andersen BL, Carbone DP, Owen DH, Presley CJ
Oncologist
March 20, 2023Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.
Divan HA, Bittoni MA, Krishna A, Carbone DP
Lung Cancer
February 24, 2023Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy".
Furuya N, He K, Carbone DP
Lung Cancer
September 12, 2022Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial.
Chaft JE, Oezkan F, Kris MG, Bunn PA, Wistuba II, Kwiatkowski DJ, Owen DH, Tang Y, Johnson BE, Lee JM, Lozanski G, Pietrzak M, Seweryn M, Byun WY, Schulze K, Nicholas A, Johnson A, Grindheim J, Hilz S, Shames DS, Rivard C, Toloza E, Haura EB, McNamee CJ, Patterson GA, Waqar SN, Rusch VW, Carbone DP, LCMC study investigators
Nat Med
September 1, 2022An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients.
Nguyen LTH, Zhang J, Rima XY, Wang X, Kwak KJ, Okimoto T, Amann J, Yoon MJ, Shukuya T, Chiang CL, Walters N, Ma Y, Belcher D, Li H, Palmer AF, Carbone DP, Lee LJ, Reátegui E
J Extracell Vesicles
September 1, 2022Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z
J Immunother Cancer
July 29, 2022Metabolic reprogramming by adenosine antagonism and implications in non-small cell lung cancer therapy.
Guan S, Suman S, Amann JM, Wu R, Carbone DP, Wang J, Dikov MM
Neoplasia
July 12, 2022Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers.
Chen K, Yang A, Carbone DP, Kanu N, Liu K, Wang R, Nie Y, Shen H, Bai J, Wu L, Li H, Shi Y, Mok T, Yu J, Yang F, Wu S, Jamal-Hanjani M, Wang J
Adv Psychosom Med
July 1, 2022Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer.
Obeng-Gyasi S, Li Y, Carson WE, Reisenger S, Presley CJ, Shields PG, Carbone DP, Ceppa DP, Carlos RC, Andersen BL
JAMA Netw Open
June 1, 2022Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer.
Valentine TR, Presley CJ, Carbone DP, Shields PG, Andersen BL
Health Psychology
June 1, 2022Longitudinal plasma proteomic profiling of patients with non-small cell lung cancer undergoing immune checkpoint blockade.
Harel M, Lahav C, Jacob E, Dahan N, Sela I, Elon Y, Raveh Shoval S, Yahalom G, Kamer I, Zer A, Sharon O, Carbone DP, Dicker AP, Bar J, Shaked Y
J Immunother Cancer
June 1, 2022Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer.
Presley CJ, Arrato NA, Shields PG, Carbone DP, Wong ML, Benedict J, Reisinger SA, Han L, Gill TM, Allore H, Andersen BL, Janse S
JTO Clin Res Rep
May 18, 2022Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients.
Zhou Z, Ding Z, Yuan J, Shen S, Jian H, Tan Q, Yang Y, Chen Z, Luo Q, Cheng X, Yu Y, Niu X, Qian L, Chen X, Gu L, Liu R, Ma S, Huang J, Chen T, Li Z, Ji W, Song L, Shen L, Jiang L, Yu Z, Zhang C, Tai Z, Wang C, Chen R, Carbone DP, Xia X, Lu S
J Hematol Oncol
April 6, 2022Small Cell Lung Cancer: Subtypes and Therapeutic Implications.
Wang WZ, Shulman A, Amann JM, Carbone DP, Tsichlis PN
Semin Cancer Biol
February 22, 2022TSAFinder: Exhaustive Tumor Specific Antigen Detection with RNAseq.
Sharpnack MF, Johnson TS, Chalkley R, Han Z, Carbone D, Huang K, He K
Bioinformatics
January 8, 2022Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH
Clin Lung Cancer
November 1, 2021A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
Williams TM, Welliver MX, Brownstein JM, Otterson G, Owen D, Pan J, Haglund KE, Shields PG, Bertino EM, Presley C, He K, Miller ED, Yang X, Knopp M, Essan JK, McElroy S, Carbone DP, Bazan JG
Int J Radiat Oncol Biol Phys
November 1, 2021Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.
Vincent BG, Szustakowski JD, Doshi P, Mason M, Guinney J, Carbone DP
JCO Precis Oncol
October 9, 2021Psychological Symptom Trajectories and Non-Small Cell Lung Cancer Survival: A Joint Model Analysis.
Andersen BL, McElroy JP, Carbone DP, Presley CJ, Smith RM, Shields PG, Brock GN
Psychosomatic Medicine
October 1, 2021Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC.
Ikarashi D, Okimoto T, Shukuya T, Onagi H, Hayashi T, Sinicropi-Yao SL, Amann JM, Nakatsura T, Kitano S, Carbone DP
JTO Clin Res Rep
September 28, 2021Lung cancer-associated T cell repertoire as potential biomarker for early detection of stage I lung cancer.
Li M, Zhang C, Deng S, Li L, Liu S, Bai J, Xu Y, Guan Y, Xia X, Sun L, Carbone DP, Hu C
Lung Cancer
September 27, 2021Lung Cancer Stem Cells and Their Clinical Implications.
Rowbotham SP, Goruganthu MUL, Arasada RR, Wang WZ, Carbone DP, Kim CF
Cold Spring Harb Perspect Med
September 1, 2021Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.
Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C
Blood Cancer Discov
July 16, 2021Real-world insights into patients with advanced NSCLC and MET alterations.
Bittoni M, Yang JC, Shih JY, Peled N, Smit EF, Camidge DR, Arasada RR, Oksen D, Boutmy E, Stroh C, Johne A, Carbone DP, Paik PK
Lung Cancer
June 4, 2021Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung.
Wang WZ, Shilo K, Amann JM, Shulman A, Hojjat-Farsangi M, Mellstedt H, Schultz J, Croce CM, Carbone DP
Adv Biochem Eng Biotechnol
June 1, 2021Genetic Ancestry Affects Somatic Alterations in Lung Cancers.
Araujo LH, Cordeiro de Lima VC, Carbone DP
Cancer Discov
May 27, 2021STK11/LKB1 loss of function is associated with global DNA hypomethylation and S-adenosyl-methionine depletion in human lung adenocarcinoma.
Koenig MJ, Agana BA, Kaufman JM, Sharpnack MF, Wang WZ, Weigel C, Navarro FCP, Amann JM, Cacciato N, Arasada RR, Gerstein MB, Wysocki VH, Oakes C, Carbone DP
Cancer Res
May 3, 2021Functional Disability Among Older Versus Younger Adults With Advanced Non-Small-Cell Lung Cancer.
Presley CJ, Arrato NA, Janse S, Shields PG, Carbone DP, Wong ML, Han L, Gill TM, Allore HG, Andersen BL
JCO Oncol Pract
April 20, 2021Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH
J Natl Compr Canc Netw
April 20, 2021Advances in epigenetic therapeutics with focus on solid tumors.
Jin N, George TL, Otterson GA, Verschraegen C, Wen H, Carbone D, Herman J, Bertino EM, He K
Clin Epigenetics
April 9, 2021Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
Memmott RM, Wolfe AR, Carbone DP, Williams TM
J Thorac Oncol
March 23, 2021The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities.
Osarogiagbon RU, Rami-Porta R, Tsao MS, Montuenga LM, Nishimura KK, Giroux D, Travis W, Asamura H, Rusch V, Carbone DP, Hirsch FR, members of the IASLC Molecular Sub-Committee and the Staging and Prognostic Factors Committee
J Thorac Oncol
February 21, 2021Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer.
Johns AC, Wei L, Grogan M, Hoyd R, Bridges JFP, Patel SH, Li M, Husain M, Kendra KL, Otterson GA, Burkart JT, Rosko AE, Andersen BL, Carbone DP, Owen DH, Spakowicz DJ, Presley CJ
J Geriatr Oncol
January 18, 2021First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Felip E, Juan-Vidal O, Alexandru A, Sakai H, Lingua A, Salman P, Souquet PJ, De Marchi P, Martin C, Pérol M, Scherpereel A, Lu S, John T, Carbone DP, Meadows-Shropshire S, Agrawal S, Oukessou A, Yan J, Reck M
Lancet Oncol
December 17, 2020Whole Brain Radiotherapy With and Without Concurrent Erlotinib in NSCLC with Brain Metastases: a multicentre, open-label, randomized, controlled phase 3 Trial.
Yang Z, Zhang Y, Li R, Yisikandaer A, Ren B, Sun J, Li J, Chen L, Zhao R, Zhang J, Xia X, Liao Z, Carbone DP
Neuro Oncol
December 2, 2020Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA
Clin Lung Cancer
July 30, 2020Verification of a blood based targeted proteomics signature for malignant pleural mesothelioma.
Cerciello F, Choi M, Sinicropi-Yao SL, Lomeo K, Amann JM, Felley-Bosco E, Stahel RA, Robinson BW, Creaney J, Pass HI, Vitek O, Carbone DP
Cancer Epidemiol Biomarkers Prev
July 29, 2020Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH
Cancer Immunol Immunother
June 18, 2020Circulating miRNAs and extracellular vesicle containing miRNAs as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
Shukuya T, Ghai V, Amann JM, Okimoto T, Shilo K, Kim TK, Wang K, Carbone DP
J Thorac Oncol
June 12, 2020Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH
Clin Lung Cancer
May 21, 2020Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
Sharpnack MF, Cho JH, Johnson TS, Otterson GA, Shields PG, Huang K, Carbone DP, He K
Lung Cancer
May 6, 2020Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D, Hoyd R, Muniak M, Husain M, Bassett JS, Wang L, Tinoco G, Patel SH, Burkart J, Miah A, Li M, Johns A, Grogan M, Carbone DP, Verschraegen CF, Kendra KL, Otterson GA, Li L, Presley CJ, Owen DH
BMC Cancer
February 25, 2020Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations.
Baek J, Owen DH, Merritt RE, Shilo K, Otterson GA, D'Souza DM, Carbone DP, Kneuertz PJ
Clin Lung Cancer
February 1, 2020New approaches to small cell lung cancer therapy : from the laboratory to the clinic.
Poirier JT, George J, Owonikoko TK, Berns A, Brambilla E, Byers LA, Carbone D, Chen HJ, Christensen CL, Dive C, Farago AF, Govindan R, Hann C, Hellmann MD, Horn L, Johnson JE, Ju YS, Kang S, Krasnow M, Lee J, Lee SH, Lehman J, Lok B, Lovly C, MacPherson D, McFadden D, Minna J, Oser M, Park K, Park KS, Pommier Y, Quaranta V, Ready N, Sage J, Scagliotti G, Sos ML, Sutherland KD, Travis WD, Vakoc CR, Wait SJ, Wistuba I, Wong KK, Zhang H, Daigneault J, Wiens J, Rudin CM, Oliver TG
J Thorac Oncol
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Carbone has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- AstraZeneca
- Regeneron Pharmaceuticals
- Bristol Myers Squibb
- Amgen
- Janssen Pharmaceuticals
- AstraZeneca UK Limited
- Merck Sharp & Dohme
Patient Comments
Very good
I am so glad I made the appointment with Dr. Carbonne. Dr. Carbonne gave me information thatI was unaware of In re: to the RET mutation I have.
We love Dr Carbone and his coworkers, he is patient, kind and hopeful
Love Dr Carbone and his staff!
All questions answered.
It is an honor to be cared for by someone with the expertise of Dr. Carbone. That's why I cam all the way from Dayton to The James. Blood draw team, nurses and all are also wonderful to me.
I have total trust in Dr. Carbone and his staff.
Dr. Carbone is incredibly knowledgeable about the cancer that I have. He has helped me tremendously.I am worried about who will fill Dr. Carbone's shoes when he retires some day.
We really appreciate Dr. Carbone and his staff. They are always there for you. God bless you all, we appreciate each and every one of you!
Dr. Carbone is just the best. I really like and trust him. Dr. Carbone was very patient with my many questions, answered each with a thorough, clear explanation, and offered both reassurances and guidance where needed.
Most excellent dr. Very much comfort with him.
Dr. Carbone took his time and helped me understand why in his opinion he did not think I needed immunotherapy.
Physician & physician asst. were well prepared with my case for a 1st visit to the James.
Dr. Carbone was very nice & informing!
Remarkable consistent staff over the years, always genuine, prepared.